First structural model of full-length human tissue-plasminogen activator: a SAXS data-based modeling study.
暂无分享,去创建一个
Mohammad Rehan | Girish Sahni | Ashish | G. Sahni | M. Rehan | Yogendra S Rathore | Kalpana Pandey | K. Pandey | Y. Rathore
[1] L. H. Schulman. Structure and function of Escherichia coli formylmethionine transfer RNA. II. Effect of modification of guanosine residues on aminoacyl synthetase recognition. , 1971, Journal of molecular biology.
[2] D. Rijken,et al. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. , 1980, Thrombosis research.
[3] M. Hoylaerts,et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. , 1982, The Journal of biological chemistry.
[4] M. Rånby,et al. Isolation of two variants of native one‐chain tissue plasminogen activator , 1982, FEBS letters.
[5] P. Seeburg,et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli , 1983, Nature.
[6] H. Jörnvall,et al. Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. , 1984, Biochemistry.
[7] S. Pizzo,et al. Catabolism of human tissue plasminogen activator in mice. , 1985 .
[8] M. Einarsson,et al. Large-scale purification of human tissue-type plasminogen activator using monoclonal antibodies. , 1985, Biochimica et biophysica acta.
[9] A. V. van Zonneveld,et al. Autonomous functions of structural domains on human tissue-type plasminogen activator. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Smith,et al. An active-site titrant for human tissue-type plasminogen activator. , 1986, The Biochemical journal.
[11] G. Larsen,et al. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator. , 1988, The Journal of biological chemistry.
[12] R. Dwek,et al. Effects of N-glycosylation on in vitro activity of Bowes melanoma and human colon fibroblast derived tissue plasminogen activator. , 1989, Biochemistry.
[13] M. Llinás,et al. Solution structure of the tissue-type plasminogen activator kringle 2 domain complexed to 6-aminohexanoic acid an antifibrinolytic drug. , 1991, Journal of molecular biology.
[14] D. Collen,et al. Strategies for the Improvement of Thrombolytic Agents , 1991, Thrombosis and Haemostasis.
[15] M. Ultsch,et al. Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4-A resolution. , 1992, Biochemistry.
[16] Dmitri I. Svergun,et al. Determination of the regularization parameter in indirect-transform methods using perceptual criteria , 1992 .
[17] I. Campbell,et al. Solution structure of the fibrin binding finger domain of tissue-type plasminogen activator determined by 1H nuclear magnetic resonance. , 1994, Journal of molecular biology.
[18] D. Botstein,et al. A faster-acting and more potent form of tissue plasminogen activator. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[19] H. Naim,et al. Intracellular Folding of Tissue-type Plasminogen Activator , 1995, The Journal of Biological Chemistry.
[20] I. Campbell,et al. The solution structure and backbone dynamics of the fibronectin type I and epidermal growth factor-like pair of modules of tissue-type plasminogen activator. , 1995, Structure.
[21] D. Svergun,et al. CRYSOL : a program to evaluate X-ray solution scattering of biological macromolecules from atomic coordinates , 1995 .
[22] R. Dwek,et al. The Activation of Type 1 and Type 2 Plasminogen by Type I and Type II Tissue Plasminogen Activator (*) , 1995, The Journal of Biological Chemistry.
[23] E. Madison,et al. Variants of Tissue-type Plasminogen Activator Which Display Substantially Enhanced Stimulation by Fibrin (*) , 1995, The Journal of Biological Chemistry.
[24] D Lamba,et al. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. , 1996, Journal of molecular biology.
[25] R. Huber,et al. Lysine 156 promotes the anomalous proenzyme activity of tPA: X‐ray crystal structure of single‐chain human tPA , 1997, The EMBO journal.
[26] R. Huber,et al. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage. , 1997, Biochemistry.
[27] D I Svergun,et al. Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing. , 1999, Biophysical journal.
[28] R. Mattes,et al. The Production of Improved Tissue-Type Plasminogen Activator in Escherichia coli , 2001, Seminars in thrombosis and hemostasis.
[29] Dmitri I. Svergun,et al. Automated matching of high- and low-resolution structural models , 2001 .
[30] Dmitri I. Svergun,et al. PRIMUS: a Windows PC-based system for small-angle scattering data analysis , 2003 .
[31] Dmitri I. Svergun,et al. Uniqueness of ab initio shape determination in small-angle scattering , 2003 .
[32] Karsten Suhre,et al. ElNémo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement , 2004, Nucleic Acids Res..
[33] Claus-Wilhelm von der Lieth,et al. GlyProt: in silico glycosylation of proteins , 2005, Nucleic Acids Res..
[34] Dmitri I Svergun,et al. Global rigid body modeling of macromolecular complexes against small-angle scattering data. , 2005, Biophysical journal.
[35] C. D. Boone,et al. Global structure of HIV-1 neutralizing antibody IgG1 b12 is asymmetric. , 2010, Biochemical and biophysical research communications.
[36] K. Goa,et al. Tissue-Type Plasminogen Activator , 1989, Drugs.